PrepTutorEJDIC

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 慢性パラコクシジオイデス症の臨床症状および診断 clinical manifestations and diagnosis of chronic paracoccidioidomycosis
2. 急性/亜急性パラコクシジオイデス症の臨床症状および診断 clinical manifestations and diagnosis of acute subacute paracoccidioidomycosis
3. パラコクシジオイデス症の治療 treatment of paracoccidioidomycosis
4. 慢性肺アスペルギルス症の臨床症状および診断 clinical manifestations and diagnosis of chronic pulmonary aspergillosis
5. パラコクシジオイデス症の菌類学および疫学 mycology and epidemiology of paracoccidioidomycosis

Immunization with Recombinant Pb27 Protein Reduces the Levels of Pulmonary Fibrosis Caused by the Inflammatory Response Against Paracoccidioides brasiliensis.

Morais EA1, Martins EM, Boelone JN, Gomes DA, Goes AM.
Mycopathologia.Mycopathologia.2014 Dec 9. [Epub ahead of print]
Paracoccidioidomycosis (PCM) is a systemic mycosis in which the host response to the infectious agent typically consists of a chronic granulomatous inflammatory process. This condition causes lesions that impair lung function and lead to chronic pulmonary insufficiency resulting from fibrosis develo
PMID 25487973

Therapeutic administration of recombinant Paracoccin confers protection against paracoccidioides brasiliensis infection: involvement of TLRs.

Alegre-Maller AC1, Mendonça FC1, da Silva TA1, Oliveira AF1, Freitas MS1, Hanna ES1, Almeida IC2, Gay NJ3, Roque-Barreira MC1.
PLoS neglected tropical diseases.PLoS Negl Trop Dis.2014 Dec 4;8(12):e3317. doi: 10.1371/journal.pntd.0003317. eCollection 2014.
BACKGROUND: Paracoccin (PCN) is an N-acetylglucosamine-binding lectin from the human pathogenic fungus Paracoccidioides brasiliensis. Recombinant PCN (rPCN) induces a T helper (Th) 1 immune response when prophylactically administered to BALB/c mice, protecting them against subsequent challenge with
PMID 25474158

Objective CT-based quantification of lung sequelae in treated patients with paracoccidioidomycosis.

Alvarez M1, Pina DR, de Oliveira M, Ribeiro SM, Mendes RP, Duarte SB, Miranda JR.
Medicine.Medicine (Baltimore).2014 Nov;93(25):e167. doi: 10.1097/MD.0000000000000167.
This study presents methodology for objectively quantifying the pulmonary region affected by emphysemic and fibrotic sequelae in treated patients with paracoccidioidomycosis. This methodology may also be applied to any other disease that results in these sequelae in the lungs.Pulmonary high-resoluti
PMID 25437031